Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These include oncology and immunology, the primary focuses of the company’s internal programs. The company’s drug discovery portfolio also includes small molecule programs being developed with Eli Lilly and Novartis.